July U.S. healthcare govt grants, clinical trials increase vs June, says Baird
rarrarorro

U.S. clinical trials and healthcare government grants for July increased over June and Y/Y, according to Baird Equity Research. 


However, U.S. outlays from the National Institutes of Health (NIH) fell 12% over June, but rose 5% Y/Y to $3.242B, after 8% YY and 13% YY growth in June and May, respectively. 



Baird estimates NIH exposure for tools names as follows: (NSTG) ~20%+, (ILMN) ~20%, (TECH) ~15%, (PKI) ~6%, (TMO) ~5%, (AVTR) ~5%, (A) ~1%-2%, (WAT) ~1%.


Clinical trials listed on clinicaltrials.gov monthly increased ~1% in July to 423,241, a rise of 10% Y/Y. Baird believes if growth continues on its YTD trajectory, this would imply ~440,290 registered clinical trials at 2022-end, a ~10.2% YY increase, ~in line with 2021âs ~10.2% YY growth.



As of August 9, there were 8,127 trials related to COVID-19 and 1,600 suspended trials. 


As of July-end, 35,854 clinical trials were funded by the NIH, 130,681 were funded by industry, 7,896 were funded by other U.S. federal agencies, and 252,521 were funded by other sources.


U.S. government grants increased ~1% vs. May-end and ~7% YY. The fastest-growing keyword among grants during June was "biomarker" +0.8% vs. June-end.